New emergency use ventilator with visual and audible alarms allows for high-flow oxygen to support COVID-19 patients with respiratory insufficiency, both invasively and non-invasively
Philips today announced its initiative to quickly scale production of its new Philips Respironics E30 ventilator as a readily available ventilation alternative during the COVID-19 crisis in situations where full-featured, critical care ventilators are not available. Philips will begin production immediately, ramping up outputs on an ongoing basis with expectations of producing 15,000 units per week in April, 2020. Designed for mass production by a team deeply experienced in respiratory care, the E30 ventilator features include:
The ability to use the device both invasively and non-invasively;
Quick set-up and simple operations, allowing healthcare providers with a wide range of skill sets to treat and monitor patients in clinical and field-hospital settings;
The ability to accept high-flow oxygen;
Recommended circuit set-ups contain a bacterial/viral filter to minimize exposure for healthcare providers when used invasively or noninvasively with example accessories that may be used, such as a full-face, non-vented (without integrated leak) mask, or helmet;
On-screen respiratory monitoring to measure and display vital ventilation type parameters such as pressure, tidal volume, respiratory rate, leak, and oxygen saturation, enabling clinicians to evaluate therapy effectiveness;
Visual and audible alarms to provide pertinent therapy information to healthcare providers.
Philips is responding to this pressing global need by quickly scaling production of the new Philips Respironics E30 ventilator with the needs of healthcare workers and COVID-19 patients in mind while also complying with medical device quality standards.
David White, Chief Scientific Officer at Philips Sleep and Respiratory Care.
“As COVID-19 continues to spread globally, healthcare providers are working diligently to treat soaring numbers of patients at a time when there are too few ventilators to provide care,” said David White, Chief Scientific Officer at Philips Sleep and Respiratory Care. “Philips is responding to this pressing global need by quickly scaling production of the new Philips Respironics E30 ventilator with the needs of healthcare workers and COVID-19 patients in mind while also complying with medical device quality standards. Our hope is that this solution will help to free-up ICU ventilators for use in treating the most severe patients.”
Philips has received Emergency Use Authorization (EUA) for the device for use only during the COVID public emergency. Status of EUA requests can be found on the FDA website. The Philips Respironics E30 is not FDA cleared or approved.
Philips is working with the relevant regulatory authorities to distribute the device globally for purchase by governments and hospitals who are experiencing ventilator shortages.